Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Overview of attention for article published in Leukemia, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 7,433)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 104 news outlets
policy: 3 policy sources
twitter: 29 X users

patent: 9 patents
guideline: 2 clinical guideline sources

Readers on

mendeley: 323 Mendeley

So far, Altmetric has seen 157 news stories from 104 outlets.

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

Cancer Network, 10 Feb 2026

Introduction Multiple myeloma is a malignancy of clonal plasma cells in the bone marrow, characterized by monoclonal…

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

UBM Medica, 10 Feb 2026

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and…

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Jotup, 09 Apr 2024

Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions…

FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Drugs.com, 08 Apr 2024

HORSHAM, PA (April 5, 2024) – Johnson

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 153 additional news stories.